Phase 2 Peripheral Neuropathy Trial, Recruiting NCT06568185 Sponsor: Universiti Sains Malaysia Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT06568185
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have been diagnosed with type 2 diabetes, based on World Health Organization (WHO) diagnostic standards
  • People who have been diagnosed with diabetic polyneuropathy (nerve damage related to diabetes), confirmed through two specific nerve symptom scoring tests called the Neurological Symptom Score (NSS) and Neuropathy Disability Score (NDS)

Who may not be able to join:

  • People who have a documented mental impairment that affects their ability to answer questions on their own
  • People who have peripheral vascular disease, which means poor blood flow in the legs and feet (such as absent foot pulses or leg pain when walking)
  • People who have had a foot or leg amputation
  • People with abnormal liver enzyme levels (confirm with trial site)
  • People who have reduced kidney function
  • People currently taking certain medications that could affect the study results, including antidepressants, anti-seizure medications, opioid pain relievers, antipsychotics, antioxidants, or specific B vitamin supplements such as methylcobalamin, pyridoxine, or other B complex preparations
  • People who are pregnant, breastfeeding, or of childbearing age without a reliable form of contraception
  • People with a known allergy to Vitamin B complex preparations (including Vitamins B1, B6, and B12) or alpha lipoic acid

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Che Nur Ain Che Abdullah, Dr., Department of Family Medicine, School of Medical Sciences University Sains Malaysia, Health Campus

Phone: +60199216023

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Universiti Sains Malaysia
Registry
ClinicalTrials.gov
Start date
27 May 2024
Est. completion
30 October 2024

Where this trial is recruiting

🇲🇾 Malaysia

Primary endpoints

To compare the mean change in Total symptom score (TSS) over 12 a week period; To compare the mean change in Neuropathic symptoms score (NSS) over 12 a week period

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov